חזרה לתוצאות החיפוש

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Mayo Clinic Arizona, Scottsdale, Arizona, United States

    Contact: Study coordinator (Rochelle Quinonez) · quinonez.rochelle@mayo.edu · 480-301-6795
    Contact: Principal Investigator (Mohamad Sonbol)

  • Highlands Oncology Group, Fayetteville, Arkansas, United States

    Contact: Study coordinator (Tina Patrick) · tpatrick@hogonc.com · +1 479 878 7098
    Contact: Principal Investigator (Joseph Thaddeus Beck)

  • Rocky Mountain Cancer Centers, Denver, Colorado, United States

    Contact: Study coordinator (Madison Schultz) · madison.schultz@usoncology.com · 303-388-4676
    Contact: Principal Investigator (Allen Cohn)

  • Hartford Hospital, Hartford, Connecticut, United States

    Contact: Study coordinator (Hayley Dunnack) · Hayley.Dunnack@hhchealth.org
    Contact: Principal Investigator (Andrew Salner)

  • Yale New Haven Hospital, New Haven, Connecticut, United States

    Contact: Study coordinator (Melissa George) · melissa.george@yale.edu
    Contact: Principal Investigator (Pamela Kunz)

  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

    Contact: Study coordinator (Alberta Lalljie) · Lalljie.Albertha@mayo.edu · 904-953-2451
    Contact: Principal Investigator (Jason Starr)

  • Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Bridget Fielder) · bfielde@emory.edu · 404-686-8210
    Contact: Principal Investigator (Amol Takalkar)

  • St Elizabeth Healthcare, Edgewood, Kentucky, United States

    Contact: Study coordinator (Lauren Willett) · lauren.willett@stelizabeth.com
    Contact: Principal Investigator (Minsig Choi)

  • LSU Medical Center, New Orleans, Louisiana, United States

    Contact: Study coordinator (Taylor Green) · tgre19@lsuhsc.edu
    Contact: Principal Investigator (Mary Maluccio)

  • Henry Ford Hospital, Detroit, Michigan, United States

    Contact: Study coordinator (Farjana Jahan) · fjahan1@hfhs.org · 313-876-1850
    Contact: Principal Investigator (Philip A Philip)

  • Mount Sinai Medical Center, New York, New York, United States

    Contact: Study coordinator (Nicole Laratta) · nicole.laratta@mssm.edu · 212-824-7876
    Contact: Principal Investigator (Edward Wolin)

  • Piedmont Healthcare, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Jeff Whorton) · Jeff.Whorton@piedmont.org
    Contact: Principal Investigator (Eyal Meiri)

  • Tennessee Oncology, Nashville, Tennessee, United States

    Contact: Study coordinator (Chasity McHone) · cmchone@tnonc.com
    Contact: Principal Investigator (Joseph Merriman)

  • TxO Austin Midtown, Austin, Texas, United States

  • Texas Oncology, Dallas, Texas, United States

    Contact: Study coordinator (Danielle Koetter) · danielle.koetter@usoncology.com
    Contact: Principal Investigator (Scott Scott Paulson)

  • Virginia Cancer Specialists, Fairfax, Virginia, United States

    Contact: Study coordinator (Kristi Ben-Barka) · kristi.ben-barka@usoncology.com
    Contact: Principal Investigator (Gregory Scott Sibley)

  • Virginia Oncology Associates, Norfolk, Virginia, United States

    Contact: Study coordinator (Amber Ingram) · amber.ingram@usoncology.com
    Contact: Principal Investigator (Jedrzej Wykretowicz)

  • Blue Ridge Cancer Center, Wytheville, Virginia, United States

    Contact: Study coordinator (Natasha Holt) · natasha.holt@usoncology.com
    Contact: Principal Investigator (David Buck)

  • Northwest Medical Specialties, Tacoma, Washington, United States

    Contact: Study coordinator (Patricia Walsh) · pwalsh@nwmsonline.com · 253-841-4296
    Contact: Principal Investigator (Mohammed N Kanaan)

  • Novartis Investigative Site, Edmonton, Alberta, Canada

  • Novartis Investigative Site, London, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Bron, France

  • Novartis Investigative Site, Clichy, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Nantes, France

  • Novartis Investigative Site, Pessac, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Erlangen, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, München, Germany

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Szeged, Hungary

  • Novartis Investigative Site, Cona, FE, Italy

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Rozzano, MI, Italy

  • Novartis Investigative Site, Pisa, PI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Milan, Italy

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Utrecht, Netherlands

  • Novartis Investigative Site, Gdansk, Poland

  • Novartis Investigative Site, Gliwice, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Novartis Investigative Site, Poznan, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Oviedo, Principality of Asturias, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, London, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)